Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of novel germline polymorphisms governing capecitabine sensitivity.

Cancer - 15 Aug 2012

O'Donnell Peter H, Stark Amy L, Gamazon Eric R, Wheeler Heather E, McIlwee Bridget E, Gorsic Lidija, Im Hae Kyung, Huang R Stephanie, Cox Nancy J, Dolan M Eileen

Abstract excerpt

BACKGROUND: Capecitabine, an oral 5-fluorouracil (5-FU) prodrug, is widely used in the treatment of breast, colorectal, and gastric cancers. To guide the selection of patients with potentially the greatest benefit of experiencing antitumor efficacy, or, alternatively, of developing toxicities, identifying genomic predictors of capecitabine sensitivity could permit its more informed use. METHODS: The objective of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Capecitabine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Fluorouracil

Share to Genome-Wide Association Study

Share to Polymorphism, Single Nucleotide

Share to Population Surveillance

Share to White People

Source

Open in PubMed Open full text

Identifiers

PMID: 22864933
DOI: 10.1002/cncr.26737
PMCID: PMC3413892

Genes

MTRR
ADCY2
SMARCAD1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of novel germline polymorphisms governing capecitabine sensitivity.PMID 22864933Read ↗

Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.Semantic proximity Read ↗

The role of pharmacogenetics in capecitabine efficacy and toxicity.Semantic proximity Read ↗

Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced Colorectal Cancer Patients: An Exploratory Study.Semantic proximity Read ↗

Capecitabine Pharmacogenetics: Historical Milestones and Progress Toward Clinical ImplementationSemantic proximity Read ↗

Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.Semantic proximity Read ↗

Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis.Semantic proximity Read ↗

[Translated article] Genetic variants and enzyme activity in citidin deaminase: Relationship with capecitabine toxicity and recommendation for dose adjustment.Semantic proximity Read ↗

Single-nucleotide polymorphisms in the genes of CES2, CDA and enzymatic activity of CDA for prediction of the efficacy of capecitabine-containing chemotherapy in patients with metastatic breast cancer.Semantic proximity Read ↗

Genetic variants and enzyme activity in citidin deaminase: Relationship with capecitabine toxicity and recommendation for dose adjustment.Semantic proximity Read ↗

Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population.Semantic proximity Read ↗

Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant.Semantic proximity Read ↗

Highlight on DPYD gene polymorphisms and treatment by capecitabine (.).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.